Streamline Health Solutions (STRM) Q3 2025 earnings summary

Executive summary

• Q3 2024 revenue declined to $4.4 million, down 28% year-over-year, mainly due to a major client non-renewal and industry headwinds, but new SaaS contracts and product enhancements partially offset losses.

• Net loss for Q3 2024 narrowed to $2.5 million from $11.9 million in Q3 2023, reflecting cost reductions and absence of prior-year impairments.

• SaaS revenue comprised 66% of total revenue in Q3 2024, up from 64% in Q3 2023, with rapid adoption of the new Evaluator Quality Module.

• Strategic restructuring at the end of fiscal 2023 led to significant cost reductions across cost of sales, SG&A, and R&D.

• Executed a 1-for-15 reverse stock split in October 2024 to regain Nasdaq compliance.

Financial highlights

• Q3 2024 revenue was $4.4 million (down from $6.1 million in Q3 2023); nine-month revenue was $13.2 million (down from $17.2 million year-over-year).

• Q3 2024 net loss was $2.5 million, improved from $11.9 million loss in Q3 2023; nine-month net loss was $8 million, improved from $17.3 million.

• Adjusted EBITDA loss for Q3 2024 was $0.3 million, compared to a gain of $0.4 million in Q3 2023.

• Cash and cash equivalents at October 31, 2024: $0.8 million, down from $3.2 million at the start of the year.

• No outstanding balance on revolving credit facility at quarter-end; $1 million drawn post-quarter.

Outlook and guidance

• Adjusted EBITDA positive run rate is now expected in the first half of fiscal 2025, with persistent profitability and significant revenue growth targeted.

• Management expects flat quarterly revenue in Q4 2024 as new client implementations offset lost revenue from the major client non-renewal.

• Anticipate sequential SaaS revenue growth in Q4 2024 and into 2025.